MGI Pharma begins Phase II trial

MOGN began a U.S. Phase II trial of its irofulven hydroxymethylacylfulvene ( MGI 114) to treat liver cancer. Irofulven, which is related to mushroom illudin toxins, is in a series of Phase I and II tr...